miR-198 functions as a tumor suppressor in breast cancer by targeting CUB domain-containing protein 1

被引:36
作者
Hu, Yingbin [1 ]
Tang, Ziyuan [1 ]
Jiang, Bonian [1 ]
Chen, Juying [1 ]
Fu, Zhongpin [1 ]
机构
[1] Cent S Univ, Xiangya Sch Med, Affiliated Canc Hosp, Dept Colorectal Surg, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
关键词
miR-198; CUB domain-containing protein 1; breast cancer; cell proliferation; cell migration; cell adhesion; RENAL-CELL CARCINOMA; MICRORNA-198; MIGRATION; CDCP1; EXPRESSION; SURVIVAL; LUNG; ADENOCARCINOMA; IDENTIFICATION; DEGRADATION;
D O I
10.3892/ol.2017.5673
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The molecular mechanisms underlying the dysregulation of microRNAs (miRs) have been previously documented in breast cancer. miR-198 has been reported to be deregulated in several human cancers. However, the detailed effects of miR-198 on breast cancer progression remain unclear. Using quantitative polymerase chain reaction analysis, we demonstrated in the present study that miR-198 was downregulated in breast cancer tissues and cell lines, and that downregulation of miR-198 was significantly correlated with lymph node metastasis. Functional studies revealed that miR-198 inhibited cell proliferation and migration and promoted cell adhesion in aggressive breast cancer cells in vitro. In addition, we observed that CUB domain-containing protcin 1 ( CDCP1) was a direct target of miR-198, and that knockdown of CDCP1 inhibited cell proliferation and migration, and promoted cell adhesion, which was similar to the effects of overexpression of miR-198. Taken together, we provide evidence to characterize the role of miR-198/CDCP1 interaction in breast cancer, which may be useful in breast cancer therapy.
引用
收藏
页码:1753 / 1760
页数:8
相关论文
共 27 条
[1]   Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma [J].
Awakura, Yasuo ;
Nakamura, Eijiro ;
Takahashi, Takeshi ;
Kotani, Hirokazu ;
Mikami, Yoshiki ;
Kadowaki, Tadashi ;
Myoumoto, Akira ;
Akiyama, Hideo ;
Ito, Noriyuki ;
Kamoto, Toshiyuki ;
Manabe, Toshiaki ;
Nobumasa, Hitoshi ;
Tsujimoto, Gozoh ;
Ogawa, Osamu .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (12) :1363-1369
[2]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[3]   The C2 domain of PKCδ is a phosphotyrosine binding domain [J].
Benes, CH ;
Wu, N ;
Elia, AEH ;
Dharia, T ;
Cantley, LC ;
Soltoff, SP .
CELL, 2005, 121 (02) :271-280
[4]   Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting [J].
Cermak, Tomas ;
Doyle, Erin L. ;
Christian, Michelle ;
Wang, Li ;
Zhang, Yong ;
Schmidt, Clarice ;
Baller, Joshua A. ;
Somia, Nikunj V. ;
Bogdanove, Adam J. ;
Voytas, Daniel F. .
NUCLEIC ACIDS RESEARCH, 2011, 39 (12) :e82
[5]   Control of mitogenic and motogenic pathways by miR-198, diminishing hepatoma cell growth and migration [J].
Elfimova, Natalia ;
Sievers, Elisabeth ;
Eischeid, Hannah ;
Kwiecinski, Monika ;
Noetel, Andrea ;
Hunt, Heike ;
Becker, Diana ;
Frommolt, Peter ;
Quasdorff, Maria ;
Steffen, Hans Michael ;
Nuernberg, Peter ;
Buettner, Reinhard ;
Teufel, Andreas ;
Dienes, Hans-Peter ;
Drebber, Uta ;
Odenthal, Margarete .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2013, 1833 (05) :1190-1198
[6]   Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients [J].
Emerling, Brooke M. ;
Benes, Cyril H. ;
Poulogiannis, George ;
Bell, Eric L. ;
Courtney, Kevin ;
Liu, Hui ;
Choo-Wing, Rayman ;
Bellinger, Gary ;
Tsukazawa, Kazumi S. ;
Brown, Victoria ;
Signoretti, Sabina ;
Soltoff, Stephen P. ;
Cantley, Lewis C. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (09) :3483-3488
[7]   Targeting microRNAs in cancer: rationale, strategies and challenges [J].
Garzon, Ramiro ;
Marcucci, Guido ;
Croce, Carlo M. .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (10) :775-789
[8]   Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen [J].
Hooper, JD ;
Zijlstra, A ;
Aimes, RT ;
Liang, HY ;
Claassen, GF ;
Tarin, D ;
Testa, JE ;
Quigley, JP .
ONCOGENE, 2003, 22 (12) :1783-1794
[9]   Epigenetic regulation of the expression of the novel stem cell marker CDCP 1 in cancer cells [J].
Ikeda, J-i ;
Morii, E. ;
Kimura, H. ;
Tomita, Y. ;
Takakuwa, T. ;
Hasegawa, J-i ;
Kim, Y. K. ;
Miyoshi, Y. ;
Noguchi, S. ;
Nishida, T. ;
Aozasa, K. .
JOURNAL OF PATHOLOGY, 2006, 210 (01) :75-84
[10]   Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung [J].
Ikeda, Jun-ichiro ;
Oda, Tomofumi ;
Inoue, Masayoshi ;
Uekita, Takamasa ;
Sakai, Ryuichi ;
Okumura, Meinoshin ;
Aozasa, Katsuyuki ;
Morii, Eiichi .
CANCER SCIENCE, 2009, 100 (03) :429-433